According to Ascendis Pharma
's latest financial reports the company has a price-to-book ratio of -27.3.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | -44.2 | -279.05% |
2022-12-31 | 24.7 | 222.96% |
2021-12-31 | 7.65 | -11.46% |
2020-12-31 | 8.64 | -13.47% |
2019-12-31 | 9.98 | 21.12% |
2018-12-31 | 8.24 | 27.11% |
2017-12-31 | 6.48 | 83.78% |
2016-12-31 | 3.53 | 0.81% |
2015-12-31 | 3.50 | |
2014-12-31 | N/A | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Akebia Therapeutics AKBA | -8.09 | -70.40% | ๐บ๐ธ USA |
Affimed
AFMD | 1.27 | -104.66% | ๐ฉ๐ช Germany |
Advaxis ADXS | -0.3314 | -98.79% | ๐บ๐ธ USA |